Preventing or minimizing damage to nerve cells is critical in reducing
long-term disability in multiple sclerosis.

Unlike the gadolinium-enhanced MRI, increases in NAA levels, as measured by
MRS, may indicate reversal of axonal loss, which strongly correlates to
improved clinical disability .

See additional important information at
http://www. SOUTH SAN FRANCISCO, Calif., AGY Therapeutics
Inc. Powe served as an associate director
in the central nervous system section of clinical research and development at
Wyeth. With its proprietary
imAGYne(TM) platform, the company has identified and characterized drug
targets and compounds to treat these diseases.

debunk neuroscientific

PRESS RELEASE COPAXONE(R) May Have Ability to Protect Against Axonal Injury Over the Long-Term in Relapsing-Remitting Multiple Sclerosis

Dr. No other approved treatment
for RRMS has been shown to have a beneficial effect on MRS scans over a
three-year period. Teva Neuroscience, Inc. Food
and Drug Administration , European Medicines Association and other
regulatory authority approvals, the regulatory environment and changes in
the health policies and structure of various countries, Teva's ability to
successfully identify, consummate and integrate acquisitions, exposure to
product liability claims, dependence on patent and other protections for
innovative products, significant operations outside the United States that
may be adversely affected by terrorism or major hostilities, fluctuations
in currency , exchange and interest rates, operating results and other
factors that are discussed in Teva's Annual Report on Form 20-F and its
other filings with the U.S.

correlates archetypes

Further, in two of the four
untreated control patients who began COPAXONE treatment after two years
of no treatment, an increase in NAA concentrations was observed during the
third year of the study, compared to the continued decline observed in the
two patients who remained untreated.

AGY Therapeutics Appoints Larry K. Powe M.D . Vice President of Clinical Development

reductionist obe

"These MRS data suggest an action of
COPAXONE in the central nervous system (CNS), resulting in a sustained
beneficial effect on cerebral axonal injury . Additional research investigating the potential neuroprotective
attributes of COPAXONE is ongoing ," explained Dr. and sanofi-aventis. Important factors that could
cause or contribute to such differences include Teva's ability to
successfully develop and commercialize additional pharmaceutical products ,
the introduction of competitive generic products, the impact of competition
from brand-name companies that sell or license their own generic products
(so called "authorized generics") or successfully extend the exclusivity
period of their branded products, the effects of competition on COPAXONE
sales , Teva's ability to rapidly integrate the operations of acquired
businesses, including its acquisition of Sicor Inc. Medical Army Corps Reserves.agyinc.

synapses unwary

Assessments included EDSS scores and annual MRI/MRS
scans.,
associate professor of neurology and director of experimental
therapeutics/clinical research, Multiple Sclerosis Center, Wayne State
University. Such
statements are based on management 's current beliefs and expectations and
involve a number of known and unknown risks and uncertainties that could
cause Teva's future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or
implied by such forward-looking statements . Securities and Exchange Commission.
Powe, M.D.

' It addresses the relationship between the brain (or entire physical organism) and religion, including religious experience, behavior, and belief.

ramachandran neurotheology

About COPAXONE

Current data suggest COPAXONE is a selective MHC class II modulator.

Teva Pharmaceutical Industries Ltd. Department of Health and Human Services and the
U. Before that, Dr . Sinai Hospital and Medical Center, Hines VA Hospital and Cook
County Hospital in Chicago and was a pediatric neurology fellow at Cook County
Children's Hospital.

hardwired hippocampi

D." COPAXONE (glatiramer acetate injection)
sustained this improvement over a three-year period, compared to
pretreatment baseline and untreated controls.com/pi/index.
At AGY, Dr. Powe served as director of clinical research at
Amgen.

neurotheology hardwired

Food and Drug Administration.
"I've spent my career trying to advance clinical practice and drug
development in the area of neuroscience.
Dr. Powe is board-certified in both pediatrics and
neurology.

newberg hardwired

This study also supports the emerging concept of
COPAXONE as a neuroprotective agent in addition to helping reduce
relapses.

Two hundred and twenty-four patients entered the nine-month
placebo-controlled study.S."
Prior to joining AGY, Dr.

lobe ramachandran

8 years. In North America , COPAXONE is
marketed by Teva Neuroscience., a privately held biotechnology company, today announced that Larry K.S. Powe will oversee the development plan and clinical strategy
for AGY's lead drug candidate, a novel therapeutic for functional recovery
after stroke and other indications involving neuroregeneration.
"His expertise in neurology and knowledge of clinical development and
regulatory demands will be critical to AGY as we work to move our lead product
candidate into its first Phase 2 trial. Army Medical Corps Reserves.

reductionist alper

03). The company
develops, manufactures, and markets generic and branded human
pharmaceuticals and active pharmaceutical ingredients. Dr. "I am compelled by the
Company's innovative approach to developing a therapeutic product with the
potential to improve the neurological deficits caused by acute cerebrovascular
disease."
Dr.

winkelman unwary

The open-label study involved 18 RRMS patients (15 of whom were followed
for three years). Khan commented on the results, "COPAXONE treatment led to increased
NAA/Cr ratios, suggesting improved cerebral axonal recovery in RRMS
patients, indicating a potential benefit on the pathways of electrical
conduction in the brain.

Early intervention with COPAXONE slows the accumulation of long-term
disability

Marco Rovaris, M. Patients continued to be
assessed for an average of 5. Significant disability in the analysis was the point at
which patients require intermittent or unilateral (one-sided) constant
assistance, such as a cane, crutch, or brace. (NASDAQ: TEVA), headquartered in
Israel, is among the top 20 pharmaceutical companies in the world.

Teva Pharmaceuticals USA is a subsidiary of Teva Pharmaceutical Industries
Ltd.html or call 1-800-887-8100 for electronic
releases. Powe also will develop regulatory strategy and
play a key role in interactions with regulatory authorities . Previously, he worked for several years for Sanofi-Aventis (then
Rhone-Poulenc Rorer), in positions including director of global medical
affairs for neurosciences and women's health, international medical director
for central nervous system diseases, and as group director for the
neuroendocrine program. Powe. I look
forward with great anticipation to helping AGY move forward its stroke product
candidate, as well as its other promising agents for central nervous system
diseases.S.

winkelman religiosity

New data presented at the European
Neurological Society Meeting (ENS) demonstrated key clinical and magnetic
resonance imaging (MRI) effects of COPAXONE (glatiramer acetate
injection) in the treatment of relapsing-remitting multiple sclerosis
(RRMS).

MRS results suggest beneficial effect of COPAXONE on cerebral axonal
injury

Brain n-acetylaspartate (NAA) levels, a marker of neuronal integrity and
function, are measured by magnetic resonance spectroscopy (MRS).D. Patient visits involved clinical
assessments and included EDSS scoring. In Europe, COPAXONE is marketed by Teva Pharmaceutical
Industries Ltd. Teva's innovative
R&D focuses on developing novel drugs for diseases of the central nervous
system. Teva Neuroscience, Inc. markets COPAXONE (glatiramer acetate
injection).
"Larry brings more than 20 years of relevant experience, ranging from his
clinical research and development work in industry, to his time spent working
for government health agencies and his academic training and clinical practice
in the area of neurology," said Cynthia Ladd, AGY's chief executive officer. AGY has an incredible dedication and
depth of expertise in this field," said Dr. At the FDA,
he served as a supervisor and leader in the bureau of drugs neurology section
and a medical officer in the drug abuse section., a privately held biopharmaceutical company, is
dedicated to discovering and developing breakthrough central nervous system
(CNS) therapeutics, including treatments for neurodegenerative diseases, CNS
injuries, stroke, cognitive diseases and schizophrenia.

shamanism persinger

Khan.
COPAXONE is indicated for the reduction of the frequency of relapses in
relapsing-remitting multiple sclerosis.
Powe has held a number of top clinical positions with leading biotechnology
and pharmaceutical companies , including Amgen, Sanofi-Aventis and Wyeth, as
well as posts with the U. He will plan,
design and direct all of the Company's clinical trial programs, including the
Phase 2a stroke study. Powe also has had a distinguished career with the U.

ramachandran unwary

Of these, 142 entered an open-label extension in
which all patients were treated with COPAXONE.

A higher proportion of patients who were continuously on COPAXONE
(glatiramer acetate injection) (n=73) did not reach significant disability
as defined by EDSS scores equal to or greater than six compared to those
who were on placebo for the first nine months, then switched to COPAXONE
(n=69) (p=0. is a subsidiary of
Teva Pharmaceutical Industries Ltd.
Forward-looking statements speak only as of the date on which they are made
and the Company undertakes no obligation to update publicly or revise any
forward-looking statement, whether as a result of new information, future
developments or otherwise. Powe holds a doctor of medicine degree from Meharry Medical College in
Nashville and has completed the executive management program at the UCLA
Anderson School of Business. He completed his residency in pediatrics and
neurology at Mt . Dr. With a robust pipeline of
clinical and preclinical candidates, the Company soon will start a Phase 2a
trial of its lead product candidate for functional recovery from stroke.

neuroscientists lobe

These results suggest early
initiation of COPAXONE in patients with active RRMS may have a positive
impact on long-term disease evolution by slowing the progression to
significant disability.S.

archetypes correlates

05270506 /050635

Powe also served the nation's military
as a colonel in the U.
For the HHS, he worked as a special assistant to the deputy director in the
bureau of health professions and health resources administration.com.

Neuroscience is an emerging field of study, sometimes also called biotheology, but which really should probably be called 'biology of religion.

synapses newberg

Safe Harbor Statement under the U.

neurotheology hardwired

Additionally, four untreated controls were followed for the first
two years.

COPAXONE is now approved in 44 countries worldwide, including the
United States, Canada, Mexico, Australia, Israel , and all the European
countries. S.S.
Dr.

religiosity reductionist

Two of these patients began therapy with COPAXONE for the
third year of the study. The most common side effects of
COPAXONE are redness, pain, swelling , itching, or a lump at the site of
injection, weakness, infection, pain, nausea, joint pain, anxiety , and
muscle stiffness.S. A drug product that could possibly restore or bring about motor
recovery after a stroke would have an immense impact on quality of life as
well as a substantial cost reduction in the care of stroke survivors.

perceive hardwired

copaxone., regulatory changes
that may prevent Teva from exploiting exclusivity periods, potential
liability for sales of generic products prior to completion of appellate
litigation, including that relating to Neurontin, the impact of
pharmaceutical industry regulation and pending legislation that could
affect the pharmaceutical industry, the difficulty of predicting U., has been appointed vice president of clinical development.C.

lobe archetypes

The data were presented by Omar Khan , M. For hardcopy releases, please see enclosed full
prescribing information. Military,
having risen to the rank of colonel in the U.

hardwired persinger

COPAXONE is a registered trademark of Teva Pharmaceutical
Industries Ltd. Private Securities Litigation Reform
Act of 1995: This release contains forward-looking statements , which
express the current beliefs and expectations of management. Dr.

About AGY Therapeutics
AGY Therapeutics Inc.

lobe correlates

Results highlighted sustained beneficial effects on cerebral axonal
injury and the value of starting COPAXONE treatment early to slow the
accumulation of long-term disability as measured by the Expanded Disability
Status Scale (EDSS). An
increase in brain NAA levels relative to creatinine (NAA/Cr ratios)
indicates a recovery of injured nerve cells or neurons in the brain . Dr. He was chief of pediatric neurology and assistant chief of
neurology at the Frankfurt Army Regional Medical Center in Germany, and a
pediatric neurologist at the Walter Reed Army Medical Center in Washington
D. For
additional information, please visit http://www.

alper persinger

, Neuroimaging Research Unit, Department of
Neuroscience, Scientific Institute and University of Ospedale San Raffaele,
Milan , presented long-term, open-label data (at almost six years) in
patients who had originally participated in a blinded MRI study which
demonstrated the efficacy of COPAXONE. Close to
90 percent of Teva 's sales are in North America and Europe. Powe's work in government includes posts at both the Department of
Health and Human Services (HHS) and the Food and Drug Administration (FDA).
He served as chief of the neurodiagnostic clinic and of pediatric neurology
and as assistant chief of neurology at the Letterman Army Medical Center in
San Francisco.

persinger perceive

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)